The most valuable asset a doctor has is the trust of their patients. Not going to risk that for a half-baked product with lukewarm support from its developer an

The most valuable asset a doctor has is the trust of their patients. Not going to risk that for a half-baked product with lukewarm support from its developer and a weak endorsement from NPR. Even if this product could aggregate data from all the PBMs, that doesn't mean the drug will be in stock at a patient's local pharmacy. Furthermore, there are many commonly prescribed drugs that are cheaper to buy outright using a discount program (not insurance). Also, there are manufacturer-to-patient rebates offered for some brand name drugs without a generic. In short, there's a lot more information that doctors already factor into their decision-making process. This tool is not compelling enough to bring into the mix.